© 2018 LP-DG® Science

Scroll down
/front/assets/b0_bg.b9f56.png
/front/assets/b1.4d847.png
/front/assets/b2.06d15.png
/front/assets/b3.e5655.png
/front/assets/b4.6dac4.png
/front/assets/b5.2ecb4.png
/front/assets/b6.feb5a.png
/front/assets/b7.9e3a3.png
/front/assets/b8.f130a.png
/front/assets/b9.660ae.png
/front/assets/b10.47360.png
/front/assets/b11.f3d7e.png
/front/assets/b12.a0e95.png
The Strain

LP-DG® (Lactobacillus paracasei CNCM I-1572) is a unique and original probiotic strain
isolated in the early 90s and characterized by SOFAR in the following years,
is demonstrated to meet all characteristics of a good probiotic.

Lactobacillus paracasei
LP-DG®

The strain was isolated in the early 90s. It was selected and identified by using the standard microbiological techniques, starting from those bacteria able to grow at acidic pH and in the presence of bile salt. 

The bacterial strain LP-DG® is a microorganism of human origin, expressly selected for its marked ability to withstand various stresses, such as the crossing of the gastric environment, and characterized by strong vitality, able to quickly rebalance the composition of the intestinal flora. 

Strain isolation: the content of Lactobacilli in the intestin of healthy individuals is approximately 109unit/gram. As a first test, human fecal samples with a high concentration of lactobacilli were considered.

The Lactobacilli were then selected based on the following criteria:

  • Stability to acid pH
  • Stability to bile salt
  • Capability to adhere to intestinal cells
  • Capability to produce lactic acid
  • In vitro high reproduction capacity 

After isolation and characterization, the strain was deposited at Pasteur Institute in Paris in 1995, under the number I-1572 CNCM.

As you can see in the first publication on the strain, at the beginning the bacterium was classified as belonging to L. casei species.  Notably, the Lactobacillus casei group consists of 3 closely related species phylogenetically (L. casei, L. paracasei and L. rhamnosus), widely used in the industrial sector of dairy products and probiotics.

More recently, following the complete sequencing of its genome and in accordance with current taxonomy in relation to Lactobacilli, the above strain was reclassified as Lactobacillus paracasei LP-DG®.   A recent publication, focused on developing a strategy to easily and rapidly characterize the species of Lactobacillus casei group, insert the LP-DG® strain within the cluster of Lactobacillus paracasei species.

So, the strain was reclassified as Lactobacillus paracasei and the current name of that strain (Lactobacillus casei LP-DG®) as follows: L. casei LP-DG® or DG® (Lactobacillus paracasei CNCM I-1572) .

The genome sequencing also revealed that the strain has a unique and important characteristic, which can be found in its protective coating. It was discovered that the LP-DG® bacterium produces exopolysaccharides (EPS) in great quantities, with a peculiar chemical structure called DG-EPS. 

The LP-DG® strain creates EPS as a natural coating, similar to a micro-encapsulation, making the strain more stress-resistant and peculiarly able to interact with the immune system.

The DG-EPS component of the strain L. casei LP-DG® was isolated, purified, and finally studied in an in vitro test to measure the behaviour of this unique function.  This study demonstrated that DG-EPS possesses immunostimulatory properties, as well as strain protective capabilities that allow LP-DG® to better adhere to the GI tract.

As a matter of fact, Lactobacillus casei LP-DG® survives the first sections of the gastrointestinal tract, where it faces the biggest stresses, and reaches the colon where it begins to interact and support the growth of other bacteria. In this way, DG modulates the gut microbiota, increasing the number of healthy bacteria, decreasing pathogenic or potentially pathogenic bacteria, reducing inflammation and interacting with the immune system. 
Lactobacillus casei LP-DG® can help nourish and support gut microbiota and promote homeostasis in the intestinal environment.    

SOFAR continues research and development on its strain LP-DG® using newest available techniques both at laboratory level as well as performing human clinical trials.

 

Cookie Policy

This website uses technical and profiling cookies collecting data in aggregate form. By closing this banner, scrolling this page or clicking any of its elements you consent to the use of cookies.

Healthcare professionals

Part of the information contained in this website is exclusively addressed to healthcare professionals. Please confirm that you are a healthcare professional. Are you a healthcare professional?

Yes, I am
No, I am not
Content to third part

This website contains links/references to third-party websites. By such links, SOFAR does not provide any guarantee nor gives its approval to their contents and quality. SOFAR does not have and does not accept any responsibility for the contents or the availability of such websites; SOFAR does not accept any liability for damage or injury resulting from the use of such contents, of whatever form. Users access such websites at their own risk. The information contained in this website is for information purposes only and not for diagnostic or therapeutic purposes. Thus, it does not substitute in any way medical and /or expert or other healthcare professionals or specialists ‘advice.

Duly noted